Stern Jennifer I, Ali Rushna, Chiang Chia-Chun, Robertson Carrie E
Department of Neurology, Headache Division, Mayo Clinic, Rochester, MN, USA.
Department of Neurological Surgery, Mayo Clinic, 201st Street Southwest, Rochester, Minnesota, 55905, USA.
Curr Neurol Neurosci Rep. 2024 Dec 12;25(1):10. doi: 10.1007/s11910-024-01387-2.
Discuss the current understanding of the pathophysiology and management of refractory trigeminal neuralgia (TN). This includes a discussion on why TN can recur after microvascular decompression and a discussion on "outside of the box" options when both first- and second-line management strategies have been exhausted.
This review discusses second- and third-line oral medication options, botulinum toxin A, repeat microvascular decompression, repeat ablative procedures, internal neurolysis, trigeminal branch blockade, and neuromodulation using TMS or peripheral stimulation. Additional management for chronic neuropathic facial pain such as deep brain stimulation, motor cortex stimulation, and focused ultrasound thalamotomy are also discussed, though evidence in trigeminal neuralgia is limited. Treatment of recurrent TN despite multiple surgeries can be challenging, and multiple minimally invasive and more invasive management options have been reported in small studies and case reports. Further studies are needed to determine an optimal stepwise approach.
讨论目前对难治性三叉神经痛(TN)病理生理学及治疗的认识。这包括探讨TN在微血管减压术后为何会复发,以及在一线和二线治疗策略均已用尽时对“非常规”治疗选择的讨论。
本综述讨论了二线和三线口服药物选择、A型肉毒毒素、重复微血管减压、重复消融手术、内部神经松解、三叉神经分支阻滞以及使用经颅磁刺激(TMS)或外周刺激的神经调节。还讨论了针对慢性神经性面部疼痛的其他治疗方法,如深部脑刺激、运动皮层刺激和聚焦超声丘脑切开术,尽管在三叉神经痛方面的证据有限。尽管进行了多次手术,复发性TN的治疗仍具有挑战性,小型研究和病例报告中已报道了多种微创和更具侵入性的治疗选择。需要进一步研究以确定最佳的逐步治疗方法。